Vesugen has exactly one human trial. It tested erectile blood flow.

Vesugen is sold online with exact injection cycles and milligram-per-day schedules, the kind of specificity that implies a clinical trial settled the question. One human trial exists. It ran in 41 older men with blood-flow problems caused by atherosclerosis, not the vascular-aging story used to market the peptide, and it had no placebo arm^[1]. Everything else written about vesugen, the mechanism, the “vascular protection” framing, the dosing, comes from cell cultures and a decades-old theory about how short peptides talk to DNA. That is a thinner foundation than the vendor copy suggests, and a reader deciding whether to inject this peptide deserves to know exactly how thin it is before making that decision.

41 men in vesugen's only published human trial PMID 25051774

What the one human study tested

The only published human study of vesugen treated 41 older men with vasculogenic erectile dysfunction from atherosclerosis, measuring penile artery blood flow before and after treatment, with no control group, no placebo, no randomization and no observational-cohort design behind it^[1]. The trial was published by Kitachev, Sazonov, Kozlov, Petrov, Sliusarev and Khavinson in 2014 in Advances in Gerontology. The peptide is transliterated in the paper as “Vezugen,” the same compound sold today as vesugen, and researchers reported clinical and instrumental improvement in blood flow after a course given alone.

That is a real result, but read what it is not:

• No control group. Nobody received a placebo or an alternative treatment to compare against.
• No blinding. Patients and clinicians both knew what was given.
• A narrow population. Older men with atherosclerosis-driven erectile dysfunction, not healthy adults chasing general “vascular health.”
• A narrow endpoint. Penile artery blood flow, not the broader anti-aging or circulation claims attached to vesugen online.

A before-and-after design in 41 people with no comparison group generates a hypothesis. It does not confirm a mechanism. Men with circulation problems who receive focused medical attention and a new injection protocol tend to report feeling better regardless of what is in the syringe. That is exactly the scenario controlled trials exist to rule out, and this one didn’t.

The rest of the evidence is cell culture, not whole animals

Vendor sites describing vesugen tend to cite “animal studies” as if rats were injected and monitored. The actual paper behind that claim, by Khavinson, Tarnovskaia, Lin’kova, Guton and Elashkina in 2014, tested vesugen in tissue cultures grown from cells taken from young and old animals, plus separate dissociated vascular endothelial cell cultures^[2]. In those dishes, vesugen increased the proliferation marker Ki-67 and, by molecular docking, appeared to bind a promoter region of the MKI67 gene. That is a cell-culture finding about gene expression. No living rat’s blood vessels were measured, let alone a living person’s.

What got compressed into “animal studies”: a gene-promoter binding experiment in dishes of cultured endothelial cells, a process that never involved a live, injected animal.

A gene-regulation theory stretched to cover one specific peptide

Vesugen belongs to a family of short, tissue-specific peptide bioregulators that the Russian gerontologist Vladimir Khavinson’s research program developed and tested across both animal experiments and clinical studies of aging-related disease^[3]. The theory behind the whole family is more specific than “peptides are good for aging”: short peptides, as few as two to seven amino acids, can enter a cell’s nucleus and interact directly with DNA, including recognizing sequences in gene promoters, and thereby switch gene expression on or off^[4]. That mechanism has been described across plant, insect, rodent and human cell systems, and it is a genuinely interesting idea about how small molecules might regulate aging-related genes.

Vesugen’s specific claim rides on top of that general theory. Lys-Glu-Asp, the tripeptide sold as vesugen, is studied in the mechanistic literature under the code KED, where it is reported to produce vasoprotective effects on atherosclerotic and restenotic endothelium, including normalizing endothelin-1 expression and increasing sirtuin1 expression^[5]. That paper, too, is cell-culture work. The jump from “this tripeptide changes gene expression in a dish of endothelial cells” to “this injection improves vascular aging in a person” is the same jump the one human trial was never designed to test.

The lab’s other well-known bioregulator, epitalon, which has its own thin trial record, follows an almost identical pattern: a cell-culture mechanism, a small clinical literature from the same research tradition, and a much bigger reputation online than either supports.

Dosing as published, not as sold

Here is the part vendor pages are least honest about. No animal study and no human study, including the one trial above, establishes a specific milligram-per-day dose or injection cycle length for vesugen. The repair pass on this research specifically went looking for a vesugen or KED dosing figure in micrograms per kilogram, the kind of number that would anchor a human dose, and found nothing usable in the vesugen literature.

No published trial has filled in vesugen's human dosing chart.

The cycle lengths and milligram schedules you find on peptide-vendor and forum sites are borrowed from general bioregulator dosing conventions used across the Khavinson catalog, not from a vesugen-specific pharmacokinetic study. Natural peptides generally have this problem: a confident-sounding protocol circulates long before anyone runs the dose-finding study that would justify it.

The practical implication is straightforward. A dose, a cycle length and an injection frequency are not facts you can borrow from a different compound’s convention and apply to vesugen. They would have to come from a dose-finding study in a defined population, comparing more than one dose against a control, and that study does not exist yet. Until it does, any specific number quoted for vesugen online is a guess dressed up as a protocol, however precise it sounds.

Side effects nobody has independently studied

The one human trial does not report an adverse-event count in its available record, and no independent, blinded safety study of vesugen exists outside the original research tradition. A clean safety record requires someone to have looked, hard, in enough people, for long enough, and nobody has done that yet. A dedicated search for vesugen-specific tolerability data, run twice with different search angles, came back with results about blood-brain-barrier drug delivery, tissue-repair peptides and organ preservation, none of which addresses vesugen in humans or animals.

That gap matters more than it sounds. People injecting vesugen today are, by definition, the first large, unmonitored safety study this compound has ever had. No published registry collects what happens to them.

Where it fits against vascular drugs that have the trials

Compare that evidence base to something with the same stated target: the vascular endothelium. Statins have been tested against placebo in a 2011 meta-analysis pooling 46 randomized controlled trials and 2,706 patients, with a significant, measurable improvement in both peripheral and coronary endothelial function^[6].

Published human studies measuring vascular or endothelial outcomes

• Vesugen: 1
• Statins (meta-analysis): 46

Vesugen's single study was uncontrolled; the statin figure is a meta-analysis of blinded, placebo-controlled trials.

One uncontrolled study against 46 controlled ones is not a close contest. If a peptide with real trial depth behind its vascular claims is what you are after, ARA-290 has considerably more clinical data than most peptides sold online, and the comparison to GHK-Cu’s human evidence gap is instructive too: that peptide at least has a documented, if thin, human record to argue over. Vesugen has one paper, in one narrow population, with no comparison group.

Bottom line: vesugen’s injection cycles and milligram doses are vendor convention. No trial produced them. The one published human study measured erectile blood flow in older men with atherosclerosis, without a placebo arm, and everything upstream of it is cell-culture work resting on a general theory about peptides and DNA.

What it would take to settle this

A trial that isolated vesugen alone, randomized participants against a placebo, pre-specified a vascular endpoint, and tested a defined dose and injection schedule would answer the question this article cannot. That trial has not been published. Until it is, any injection cycle or milligram-per-day figure presented online as settled for vesugen is a confidence the published record does not back.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.